Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06436144
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-30
First Post:
2024-05-21
Brief Title:
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC
Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Organization:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Organization Data
Organization:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Class:
OTHER
Study ID:
ABC2024521
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lead Sponsor Class:
OTHER
Responsible Party:
Yong He
Responsible Party Title:
Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Old Name:
None
Old Organization:
None